Business Context and Reporting Period
This Form 8-K is a current report filed by BeiGene, Ltd. on January 8, 2018, covering events occurring on January 7 and January 8, 2018. The filing primarily addresses regulatory disclosure obligations regarding investor communications and a significant strategic partnership.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Events
- Regulation FD Disclosure: The Company participated in the 36th Annual J.P. Morgan Healthcare Conference in San Francisco during the week of January 7, 2018. A presentation delivered to investors is attached as Exhibit 99.1.
- Strategic Partnership: On January 8, 2018, BeiGene entered into an exclusive license agreement with Mirati Therapeutics. This agreement covers the development, manufacturing, and commercialization of Mirati's sitravatinib in Asia (excluding Japan), Australia, and New Zealand.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.2) detailing the Mirati Therapeutics agreement. The document explicitly states that the investor presentation (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific financial guidance or forward-looking projections are detailed within the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 for the full content of the J.P. Morgan Healthcare Conference presentation.
- Examine Exhibit 99.2 for the complete terms of the exclusive license agreement with Mirati Therapeutics regarding sitravatinib.
- Verify the specific geographic scope of the new agreement (Asia excluding Japan, Australia, and New Zealand).
- Note that this filing does not contain audited financial statements or updated financial metrics.